Linesight Poised for Future Global Expansion With New CEO
3.2.2021 14:57:00 EET | Business Wire | Press release
Multinational consultancy firm, Linesight, announced today that it is promoting Paul Boylan to the position of Chief Executive Officer (CEO) and welcoming Tom Dempsey as COO.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210203005457/en/
Paul Boylan, Linesight CEO (Photo: Business Wire)
Boylan has been appointed as the new Chief Executive Officer (CEO) and will be taking over from Gerard Campbell who will remain on the Executive Board throughout 2021. Boylan joined Linesight in 2002 and has amassed over twenty-five years of experience in the global construction industry. He has played a pivotal role in growing Linesight’s client base and expanding the company’s reach geographically.
“Gerard Campbell has made an enormous contribution to Linesight over four decades and will continue to provide valuable strategic inputs on our Executive Board in the coming year,” said Boylan “We are focused on building on the strong foundation Gerard has established, working with our highly skilled and committed global teams who are empowered and motivated to collaborate with our clients for success. Our ability to be agile and rapidly respond to market and client needs will remain a key tenet of our strategic and operational approach going forward.”
Tom Dempsey has also recently joined Linesight’s Executive Leadership team as the new Chief Operations Officer (COO). Dempsey has extensive experience in the pharmaceutical and technology sectors and has held a variety of roles, include VP Global Operations, at Hewlett Packard in the Real Estate function. “I am thrilled to be taking on the role of COO and look forward to supporting Linesight’s ambitious goals of becoming a global authority in construction project, program, scheduling and cost management,” said Dempsey “This is truly an exciting time in Linesight’s evolution as an industry innovator.”
Over the past three years Linesight has extensively expanded its client base in several key sectors, including the Data Center, Life Sciences, Commercial, High-Tech Industry and Residential sectors, in its targets regions of the Americas, Europe, APAC and the Middle East. Year on year revenue growth has been profitable at over 20% owing to the explicit and strategic evolution of the company. Linesight now has twenty-two offices worldwide and over seven hundred skilled team members. With new senior leadership in place Linesight is well structured to deliver on its ambitious growth aspirations which include geographical and team expansion to maximize value for their clients.
ENDS
About Linesight
Linesight is a multinational consultancy firm with over 45 years' experience, providing cost, schedule, program and project management services to a multitude of sectors including Life Sciences, Commercial, Data Centers, High-Tech Industrial, Residential, Hospitality, Aviation, Transport and Infrastructure, Healthcare and Retail. Linesight’s specialist project teams, each with specific skills and experience, provide faster project delivery, greater cost efficiency, predictability in project planning and maximum value for money for their clients. For further information, please visit http://www.linesight.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005457/en/
Contact information
Media Contact UK
Stuart Maclure at ing.media for Linesight
T: +44 (0) 207 247 8334
E: stuart.maclure@ing-media.com
Media Contact USA
Cameron Thomas at Verbfactory for Linesight
T: (416) 660-9801
E: cameron@verbfactory.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom